Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2018 Jan 23;8(1):e017653.
doi: 10.1136/bmjopen-2017-017653.

Narrative medicine-based intervention in primary care to reduce polypharmacy: results from the cluster-randomised controlled trial MultiCare AGENDA

Affiliations
Randomized Controlled Trial

Narrative medicine-based intervention in primary care to reduce polypharmacy: results from the cluster-randomised controlled trial MultiCare AGENDA

Ingmar Schäfer et al. BMJ Open. .

Abstract

Objectives: To determine if patient-centred communication leads to a reduction of the number of medications taken without reducing health-related quality of life.

Design: Two-arm cluster-randomised controlled trial.

Setting: 55 primary care practices in Hamburg, Düsseldorf and Rostock, Germany.

Participants: 604 patients 65 to 84 years of age with at least three chronic conditions.

Interventions: Within the 12-month intervention, general practitioners (GPs) had three 30 min talks with each of their patients in addition to routine consultations. The first talk aimed at identifying treatment targets and priorities of the patient. During the second talk, the medication taken by the patient was discussed based on a 'brown bag' review of all the medications the patient had at home. The third talk served to discuss goal attainment and future treatment targets. GPs in the control group performed care as usual.

Primary outcome measures: We assumed that the number of medications taken by the patient would be reduced by 1.5 substances in the intervention group and that the change in the intervention group's health-related quality of life would not be statistically significantly inferior to the control group.

Results: The patients took a mean of 7.0±3.5 medications at baseline and 6.8±3.5 medications at follow-up. There was no difference between treatment and control group in the change of the number of medications taken (0.43; 95% CI -0.07 to 0.93; P=0.094) and no difference in health-related quality of life (0.03; -0.02 to 0.08; P=0.207). The likelihood of receiving a new prescription for analgesics was twice as high in the intervention group compared with the control group (risk ratio, 2.043; P=0.019), but the days spent in hospital were reduced by the intervention (-3.07; -5.25 to -0.89; P=0.006).

Conclusions: Intensifying the doctor-patient dialogue and discussing the patient's agenda and personal needs did not lead to a reduction of medication intake and did not alter health-related quality of life.

Trial registration number: ISRCTN46272088; Pre-results.

Keywords: chronic care model; multimorbidity; narrative based medicine; polypharmacy.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1
Sampling and response rates of patients. *‘Multimorbidity’ is defined as at least 3 out of 42 ICD-10-based diagnosis groups. ICD, International Classification of Diseases.
Figure 2
Figure 2
Changes of medication in treatment and control group between baseline and follow-up. Example reading of C09 angiotensin inhibitor: 5.4% of intervention group patients and 3.3% of control group patients took an angiotensin inhibitor at baseline but had discontinued this medication at follow-up. At the same time, 3.3% of control group patients and 4.4% of intervention group patients did not have an angiotensin inhibitor at baseline but had obtained this medication at follow-up. *Statistically significant difference (P≤0.05 Benjamini-Hochberg adjusted for 45 statistical tests). O, change in intervention group; X, change in control group.

References

    1. Violan C, Foguet-Boreu Q, Flores-Mateo G, et al. . Prevalence, determinants and patterns of multimorbidity in primary care: a systematic review of observational studies. PLoS One 2014;9:e102149 10.1371/journal.pone.0102149 - DOI - PMC - PubMed
    1. Marengoni A, Angleman S, Melis R, et al. . Aging with multimorbidity: a systematic review of the literature. Ageing Res Rev 2011;10:430–9. 10.1016/j.arr.2011.03.003 - DOI - PubMed
    1. Gijsen R, Hoeymans N, Schellevis FG, et al. . Causes and consequences of comorbidity: a review. J Clin Epidemiol 2001;54:661–74. 10.1016/S0895-4356(00)00363-2 - DOI - PubMed
    1. Marengoni A, Onder G. Guidelines, polypharmacy, and drug–drug interactions in patients with multimorbidity. BMJ 2015;350:h1059 10.1136/bmj.h1059 - DOI - PubMed
    1. Boyd CM, Darer J, Boult C, et al. . Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases. JAMA 2005;294:716–24. 10.1001/jama.294.6.716 - DOI - PubMed

Publication types

Associated data